Details of the Drug

General Information of Drug (ID: DMMBQ20)

Drug Name
CPI-818
Indication
Disease Entry ICD 11 Status REF
T-cell lymphoma 2A90 Phase 1 [1]
Drug Type
Small molecular drug
Cross-matching ID
PubChem CID
134517711
TTD ID
D1YZ5O
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell-specific kinase (ITK) TT3C80U ITK_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03952078) A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.